Osteoarthritis

Osteoarthritis (OA) is the most common joint disorder, which is due to aging and wear and tear on a joint.

Programs + Services


Rheumatology

The Division of Rheumatology at Tufts Medical Center in Boston offers comprehensive evaluation, consultation and management of arthritis and rheumatic disease.
More information about programs and services


Osteoarthritis Program

The Osteoarthritis Program at Tufts Medical Center in Boston is home to world-renowned experts in researching, diagnosing and treating OA.
More information about programs and services


Center for Complementary and Integrative Medicine

The Center for Complementary and Integrative Medicine in the Division of Rheumatology at Tufts Medical Center works to use alternative therapies to help patients with arthritis and rheumatic diseases.
More information about programs and services

Doctors + Care Team

Timothy E. McAlindon, MD, MPH

Timothy E. McAlindon, MD, MPH

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Division of Rheumatology; Professor, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5990
Fax #: 617-636-2388

Osteoarthritis, general rheumatology, lupus

View Full Profile for Timothy E. McAlindon, MD, MPH

Robert A. Kalish, MD

Robert A. Kalish, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Rheumatology Education; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5990
Fax #: 617-636-2388

General rheumatology, Lyme disease

View Full Profile for Robert A. Kalish, MD

Senada Arabelovic, DO

Senada Arabelovic, DO

Accepting New Patients

Virtual Appointments Available

Title(s): Rheumatologist; Chair, Women in Medicine Committee (WiMS), Assistant Professor of Medicine, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5990
Fax #: 617-636-2388

General rheumatology, transitioning young adults with autoimmune diseases to the adult rheumatology clinic, pregnancy in rheumatologic disease

View Full Profile for Senada Arabelovic, DO

Steven C. Vlad, MD, PhD

Steven C. Vlad, MD, PhD

Accepting New Patients

Virtual Appointments Available

Title(s): Rheumatologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5990
Fax #: 617-636-2388

General rheumatology, spondyloarthropathies, psoriatic arthritis and anklylosing spondylitis

View Full Profile for Steven C. Vlad, MD, PhD

William F. Harvey, MD, MSc, FACR

William F. Harvey, MD, MSc, FACR

Accepting New Patients

Virtual Appointments Available

Title(s): Clinical Director, Rheumatology; Rheumatologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5990
Fax #: 617-636-2388

Osteoarthritis, general rheumatology, musculoskeletal ultrasound

View Full Profile for William F. Harvey, MD, MSc, FACR

Research + Clinical Trials


Neurobiological Mechanisms of Mind-body Therapy for Knee Osteoarthritis

This study aims to provide crucial knowledge about the neurobiological mechanisms underlying mind-body therapy for knee osteoarthritis (OA). We will investigate the central mechanism of knee OA pain using brain imaging technology to evaluate how brain function and structure change in response to mind-body exercise over time.

Participants will be randomized to either a Tai Chi or Wellness Education class and asked to come to Tufts Medical Center twice a week for 12 weeks, along with a baseline and follow-up visit (26 study visits). The findings will lead to the establishment of a new treatment paradigm in OA and have broad application to the management of chronic musculoskeletal pain.
More information about research and clinical trials


A Cross-sectional Observational Study Evaluating the Effect of intra-Articular Steroids or Placebo Previously Injected in the target Knee Joint of Subjects on structural Progression of Knee Osteoarthritis.

The purpose of the study is to evaluate for long term changes in pain and function in knee osteoarthritis and also to ascertain differences in health care utilization among subjects who participated in the randomized controlled trial on effect of intra-articular steroids on structural progression of knee osteoarthritis (IACS)
More information about research and clinical trials


A Randomized, Double-Blind, Placebo-Controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects with Chronic, Moderate-to severe Osteoarthritis Knee Pain

The study evaluates the analgesic efficacy on pain with walking of a one-time knee injection for patients with moderate to severe knee osteoarthritis. CNTX-4975-05 is the investigational drug that has not been approved by the FDA. The study drug is a long-acting, non-opioid analgesic drug candidate designed to provide pain relieve. Subjects will be randomly assigned to one of two groups: study drug group, or a placebo group.
More information about research and clinical trials


A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and NSAID-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain due to Osteoarthritis of the Knee or Hip

This study evaluates the efficacy and safety of fasinumab compared to placebo, diclofenac, and celecoxib (diclofenac and celecoxib are standard-of-care non-steroidal anti-inflammatory drugs, NSAIDs, used for moderate-to-severe pain due to OA). The study drug will be administered for up to 24 weeks in patients with OA of the knee or hip. Fasinumab aims to selectively block nerve growth factor (NGF), a protein that causes pain. Blocking NGF may reduce pain due to OA of the hip and knee. Fasinumab is being test and is not approved for use in pain management by the United States Food and Drug Administration (FDA).
More information about research and clinical trials


A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and NSAID-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain due to Osteoarthritis of the Knee or Hip 

This study evaluates the efficacy and safety of fasinumab compared to placebo, diclofenac, and celecoxib (diclofenac and celecoxib are standard-of-care non-steroidal anti- inflammatory drugs, NSAIDs, used for moderate-to-severe pain due to OA). The study drug will be administered for up to 24 weeks in patients with OA of the knee or hip. Fasinumab aims to selectively block nerve growth factor (NGF), a protein that causes pain. Blocking NGF may reduce pain due to OA of the hip and knee. Fasinumab is being test and is not approved for use in pain management by the United States Food and Drug Administration (FDA). 
More information about research and clinical trials


Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study (ROCCELLA Study) 

The main purpose of this study is to evaluate safety and efficacy of three doses of the study drug, GLPG1972 compared to placebo. The study drug will be administered as an oral pill daily. This drug aims to reduce the cartilate breakdown in patients with knee osteoarthritis (OA). GLPG1972 is being tested and is not approved for use for patients with knee OA by the United States Food and Drug Administration (FDA). 
More information about research and clinical trials


MRI Qualification for Imaging Facility Sites, participating in the Galapagos NV / "Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study." 

You are invited to take part in an assessment of MRI (Magnetic Resonance Imaging) equipment. The MRI examination will be one study visit that will take place at Tufts Medical Center and will take up to 1 hour. It is important to be aware that the images will only be analyzed for evaluating the quality of the images. The images will not be evaluated for any diseases. 
More information about research and clinical trials